血栓通注射液联合尤瑞克林、丁苯酞治疗急性脑梗死的效果及对基质金属蛋白酶、神经因子水平的影响  

Therapeutic effect of Xueshuantong injection combined with urinary kallindinogenase and butylphthalide on acute cerebral infarction and its influence on the levels of matrix metalloproteinases and neuronal factors

作　　者：杨军 汪捷 文洪波 YANG Jun;WANG Jie;WEN Hong-bo(Department of Neurology,Nanjing Lishui District People's Hospital,Nanjing,Jiangsu,211200,China)

机构地区：[1]南京市溧水区人民医院神经内科,江苏南京211200

出　　处：《心血管康复医学杂志》2024年第4期466-470,共5页Chinese Journal of Cardiovascular Rehabilitation Medicine

基　　金：江苏大学临床医学科技发展基金项目(JLY20180209)。

摘　　要：目的:探讨血栓通注射液联合尤瑞克林、丁苯酞治疗急性脑梗死的效果及对基质金属蛋白酶(MMP)、神经因子水平的影响。方法:选择2022年1月至2022年6月我科收治的急性脑梗死患者92例,以随机数字表法分为对照组和研究组,各46例,对照组采用尤瑞克林+丁苯酞治疗,研究组在对照组基础上联合血栓通注射液治疗,治疗3周后,对比两组治疗效果,血流动力学及MMP、神经因子水平变化。结果:与对照组比较,研究组治疗后总有效率(82.61%比97.83%)及平均血流速率(Vm)[(25.91±2.94)cm/s比(29.88±2.18)cm/s]、神经生长因子(NGF)[(69.91±6.54)pg/ml比(79.07±8.72)pg/ml]、神经营养因子(NTF)[(4.12±1.30)ng/ml比(4.85±0.93)ng/ml]水平显著提高,外周阻力(Rv)[(89.33±14.89)kPa·s/m比(79.89±12.32)kPa·s/m]、动态阻力(DR)[(37.81±5.18)kPa比(33.98±4.6)kPa]、MMP-2[(248.63±12.06)μg/L比(207.06±12.06)μg/L]、MMP-9[(234.99±12.86)μg/L比(200.30±11.78)μg/L]、神经元特异性烯醇化酶(NSE)[(16.14±2.81)μg/L比(12.66±2.77)μg/L]水平均显著降低(P<0.05或<0.01)。结论:临床治疗急性脑梗死采用血栓通注射液联合尤瑞克林、丁苯酞有助于提高治疗效果,促进脑血流动力学改善,也能进一步调节基质金属蛋白酶和神经因子水平,值得推广。Objective:To investigate the therapeutic effect of Xueshuantong injection combined with urinary kallindinogenase and butylphthalide on acute cerebral infarction(ACI)and its influence on the levels of matrix metalloproteinases(MMP)and neuronal factors.Methods:A total of 92 ACI patients treated in our department from January 2022 to June 2022 were selected,divided into control group(n=46)and study group(n=46)using random number table method.The control group was treated with urinary kallindinogenase+butylphthalide,and the study group was treated with Xueshuantong injection on the basis of the control group.After 3-week treatment,therapeutic effect,hemodynamics,levels of MMP and neuronal factors were compared between two groups.Results:Compared with the control group after treatment,there were significant rise in total effective rate(82.61%vs.97.83%),mean blood velocity(Vm)[(25.91±2.94)cm/s vs.(29.88±2.18)cm/s],levels of nerve growth factor(NGF)[(69.91±6.54)pg/ml vs.(79.07±8.72)pg/ml]and neurotrophic factors(NTF)[(4.12±1.30)ng/ml vs.(4.85±0.93)ng/ml],and significant reductions in peripheral resistance(Rv)[(89.33±14.89)kPa·s/m vs.(79.89±12.32)kPa·s/m],dynamic resistance(DR)[(37.81±5.18)kPa vs.(33.98±4.6)kPa],levels of MMP-2[(248.63±12.06)μg/L vs.(207.06±12.06)μg/L],MMP-9[(234.99±12.86)μg/L vs.(200.30±11.78)μg/L]and neuron specific enolase(NSE)[(16.14±2.81)μg/L vs.(12.66±2.77)μg/L]in study group(P<0.05 or<0.01).Conclusion:Xueshuantong injection combined with urinary kallindinogenase and butylphthalide can help to improve the therapeutic effect,promote the improvement of cerebral hemodynamics,and further regulate the levels of matrix metalloproteinases and neuronal factors in patients with acute cerebral infarction,which is worthy of promotion.

关 键 词：脑梗死 基质金属蛋白酶类 活化白细胞黏附分子 血小板聚集抑制剂 

分 类 号：R541.61[医药卫生—心血管疾病]